AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity
- PMID: 19487444
- PMCID: PMC2715641
- DOI: 10.1128/AAC.00400-09
AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity
Abstract
AFN-1252, a potent inhibitor of enoyl-acyl carrier protein reductase (FabI), inhibited all clinical isolates of Staphylococcus aureus (n = 502) and Staphylococcus epidermidis (n = 51) tested, including methicillin (meticillin)-resistant isolates, at concentrations of <or=0.12 microg/ml. In contrast, AFN-1252 was inactive (MIC(90), >4 microg/ml) against clinical isolates of Streptococcus pneumoniae, beta-hemolytic streptococci, Enterococcus spp., Enterobacteriaceae, nonfermentative gram-negative bacilli, and Moraxella catarrhalis. These data support the continued development of AFN-1252 for the treatment of patients with resistant staphylococcal infections.
References
-
- Campbell, J. W., and J. E. Cronan, Jr. 2001. Bacterial fatty acid biosynthesis: targets for antibacterial drug discovery. Annu. Rev. Microbiol. 55:305-332. - PubMed
-
- Clinical and Laboratory Standards Institute. 2007. Performance standards for antimicrobial susceptibility testing; eighteenth informational supplement, M100-S17, vol. 27, no. 1. Clinical and Laboratory Standards Institute, Wayne, PA.
-
- Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; M7-A7, approved standard, 7th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
-
- Reference deleted.
-
- Reference deleted.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous